Takeda Pharmaceutical (NYSE:TAK) Issues FY 2026 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 3.009-3.009 for the period, compared to the consensus EPS estimate of 1.570. The company issued revenue guidance of $29.6 billion-$29.6 billion, compared to the consensus revenue estimate of $29.0 billion.

Analyst Ratings Changes

A number of research analysts have weighed in on TAK shares. Wall Street Zen upgraded Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Finally, Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Moderate Buy”.

Takeda Pharmaceutical Stock Performance

TAK opened at $16.64 on Friday. Takeda Pharmaceutical has a 12-month low of $12.99 and a 12-month high of $18.90. The stock has a market cap of $52.95 billion, a price-to-earnings ratio of 42.66 and a beta of -0.06. The business has a 50 day moving average of $17.62 and a 200-day moving average of $16.41. The company has a quick ratio of 0.65, a current ratio of 1.19 and a debt-to-equity ratio of 0.56.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a return on equity of 11.23% and a net margin of 4.31%.The company had revenue of $6.90 billion during the quarter. On average, equities research analysts expect that Takeda Pharmaceutical will post 1.5 earnings per share for the current year.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds have recently made changes to their positions in TAK. UBS Group AG lifted its position in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after buying an additional 1,869,323 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Takeda Pharmaceutical by 132.1% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after purchasing an additional 1,610,088 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in Takeda Pharmaceutical by 407.9% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after purchasing an additional 1,426,184 shares during the last quarter. Van ECK Associates Corp lifted its holdings in Takeda Pharmaceutical by 98.4% during the 4th quarter. Van ECK Associates Corp now owns 2,305,397 shares of the company’s stock worth $35,941,000 after purchasing an additional 1,143,117 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in Takeda Pharmaceutical by 1,070.7% during the 4th quarter. Voloridge Investment Management LLC now owns 962,502 shares of the company’s stock worth $15,005,000 after purchasing an additional 880,289 shares during the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.